Hologic Inc. (NASDAQ:HOLX) said Tuesday it has completed its acquisition by funds managed by Blackstone Inc. (NYSE:BX) and TPG Inc. (NASDAQ:TPG).
Hologic's common stock has ceased trading and will be delisted from the Nasdaq Stock Market.
Acquisition Details
The company agreed in October to be acquired in a deal valuing it at about $18.3 billion. The purchase price of $79 per share represented a 46% premium to Hologic's closing share price on May 23, 2025.
With the transaction now complete, shareholders will receive $76 per share in cash, along with a non-tradable contingent value right (CVR) worth up to $3 per share. The CVR will be paid in two potential installments of up to $1.50 each.
The CVR will be distributed at closing and is tied to Hologic's Breast Health business achieving specific global revenue milestones in fiscal 2026 and 2027.
The deal marks a significant shift for the women's health-focused company. Backing from Blackstone and TPG is expected to support its innovation and growth initiatives.
Following the completion of the transaction, Hologic appointed José (Joe) E. Almeida as chief executive officer, effective immediately. He succeeds Stephen MacMillan, who recently retired after more than 12 years as chairman, president and CEO.
Photo via Shutterstock